Navigation Links
Study Shows Nonprescription LCD Topical Solution is More Effective than Prescription-Strength Calcipotriol Cream for Moderate Plaque Psoriasis
Date:3/10/2009

- Significant efficacy differences widen 6 weeks after treatment stops -

SAN FRANCISCO, March 10 /PRNewswire/ -- A nonprescription topical solution made with a new formulation of liquor carbonis distillate (LCD), known as PSORENT(R), is significantly more effective than prescription-strength calcipotriol cream in improving and controlling the symptoms of plaque psoriasis, according to research findings presented at the American Academy of Dermatology's 2009 Annual Meeting. Significant efficacy differences favoring LCD solution over a 12-week treatment phase were also pronounced after treatment stopped, during a 6-week regression phase that was the focus of the today's presentation. The research, a randomized, investigator-blind, active-controlled study of 60 adults with moderate plaque psoriasis, was conducted by a team of investigators at the Clinical Unit for Research Trials in Skin (CURTIS) at Massachusetts General Hospital in Boston, Massachusetts.

"We knew, based on the preliminary study results we presented at the summer AAD, that in the treatment phase of this study, twice-daily LCD outperformed calcipotriol cream for control of psoriasis symptoms," said Alexa Kimball, MD, MPH, a CURTIS researcher who was also a study investigator and author. "But we were encouraged by the fact that the improvements also persisted longer after patients stopped their twice-daily treatments for six weeks."

The team's conclusions are based on data from 55 patients who received treatment for up to 12 weeks and 43 patients who returned for re-assessment 6 weeks after treatment stopped. Its main findings include:

  • LCD therapy produced a significantly better reduction in psoriasis severity than calcipotriol therapy in 12 weeks based on PASI 50 (67% vs. 36%) and PASI 75 (37% vs. 0%) achievers and percent change in PASI (58% vs 37%) and PGA scores (P<0.05).
  • Significantly fewer LCD-treated patients than calcipotriol-treated patients regressed to initial disease severity within 6 weeks of stopping treatment (P</=0.005).
  • PASI scores and PGA scores worsened significantly after stopping calcipotriol therapy but not after stopping LCD therapy (P</=0.05).
  • Within 6 weeks of completing treatment, LCD-treated patients reported better control of a range of psoriasis symptoms -- including scaling/flaking, redness, skin texture, itch, overall appearance, and overall discomfort -- than calcipotriol-treated patients.
  • Patients' rated LCD solution and calcipotriol cream as comparable for convenience, irritation potential, and aesthetic attributes (e.g., staining, scent).

Dr. Kimball said their results should be important to a wide range of psoriasis patients because they indicate that this nonprescription therapy, "has a compelling efficacy and aesthetic profile." Psoriasis experts asked to comment on the study seem to agree on its significance.

"Because no single treatment is right for everyone, dermatologists are always looking for new ways to improve outcomes for their psoriasis patients," said Mark Lebwohl, MD, chairman of the Department of Dermatology at The Mount Sinai School of Medicine in New York. "The results of this trial suggest that LCD may be an appropriate treatment choice for psoriasis patients with mild or moderate disease."

Jerry Bagel, MD, Windsor Dermatology, said that "a new therapy that is easy for patients to use, cosmetically preferable, and that has greater proven efficacy than a prescription medication with the safety profile of an OTC, is certainly good news for psoriasis patients."

About PSORENT(R)

PSORENT(R) is a new leave-on topical solution that has the proven efficacy of a prescription medication but is available OTC. This aesthetically advanced, quick-drying, solution is highly effective, easy and pleasant to use, and may help increase patient satisfaction and compliance.

PSORENT(R) is supplied in 100 mL bottles fitted with a convenient "dab-on" applicator that allows patients to treat themselves without touching the medication or their plaques. PSORENT(R) is sold through physicians' offices and is available online at www.psorent.com.

About NeoStrata

PSORENT(R) is marketed by NeoStrata Company, Inc. Located in Princeton, NJ, NeoStrata develops and markets advanced therapeutic and cosmetic dermatological products through consumer outlets and physicians' offices in the United States and internationally through physicians' offices, pharmacies, and spas.

More information is available at www.neostrata.com and www.psorent.com.

    Media contact
    Barbara Green
    NeoStrata Company, Inc.
    609-986-2971
    bgreen@NeoStrata.com


'/>"/>
SOURCE NeoStrata Company, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. UM study reveals demographic trend of the Jewish population in Broward County
2. Shootings Linked to Alcohol-to-Go Outlets, Study Finds
3. Study shows that maintenance rituximab is useful for advanced indolent lymphoma
4. Study Links Blood Type and Pancreatic Cancer
5. New study identifies risk factors in severity of flat head syndrome in babies
6. New Study Shows That One-Third of Shelter Youth Have Been Institutionalized; Almost One-Half Suffered Violence in the Home
7. Beaumont Launches 1st U.S. Adult Human Stem Cell Study for Stress Urinary Incontinence
8. Common Approaches to Member Retention by Health Insurance Plans are Ineffective, New Study Shows
9. Celator(R) Pharmaceuticals Enrolls First Patient in Its Phase 2 Study of CPX-351 in Acute Myeloid Leukemia in First Relapse
10. Study Shows 80% of Adults with Peripheral Arterial Disease Go Undiagnosed
11. Study finds pay for performance stimulates changes in medical practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... "The World Market for Companion Diagnostic Tests" report to ... World Market for Companion Diagnostics The World ... diagnostic and personalized medicine diagnostics. Market analysis in the report ... Diagnostics Test Market (In Vitro Diagnostic Kits) by Region (N. ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
Breaking Medicine Technology: